Susquehanna Maintains a 'Positive' on Merit Medical Systems (MMSI) Followin Q1 Results
Susquehanna maintains a 'Positive' rating on Merit Medical Systems Inc. (Nasdaq: MMSI). Price target $16.00.
Susquehanna analyst says, "We are maintaining our Positive rating on Merit Medical following yesterday's release of 1Q09 results. In what has been a growing trend in Medtech this earnings season - light on revenue, bottom-line meet or beat - MMSI reported total sales of $58.4 mln (+9% Y/Y), which was just a bit shy of estimates ($500K below our estimate and $1 mln below consensus), and operating EPS of $0.20 that topped estimates ($0.02 above our estimate). Importantly, the company closed the recent Alveolus and Biosearch Medical Products acquisitions, which add an immediate revenue base (not solely R&D projects), perhaps allowing to Merit deliver double-digit top and bottom-line growth for the next two years. Further, MMSI should have the opportunity for meaningful geographic expansion, as the Alveolus footprint was formerly only about two-thirds of the country (and was very limited OUS)."
Merit Medical Systems, Inc produces single-use medical products. The products are designed to enable physicians and other health care professionals to perform interventional and diagnostic procedures safely and effectively.
Related Categories
Analyst CommentsStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
